Description
An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.
Chemical properties
| Chemical formula | Net charge | Average mass |
|---|---|---|
| C20H32N5O10P | 0 | 533.470 |
Nomenclature
| IUPAC | SMILES | InChI | InChIKey | Synonyms |
|---|---|---|---|---|
| bis{[(tert-butoxycarbonyl)oxy]methyl} {[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonate | N1(C2=C(C(N)=NC=N2)N=C1)CCOCP(OCOC(OC(C)(C)C)=O)(=O)OCOC(OC(C)(C)C)=O | InChI=1S/C20H32N5O10P/c1-19(2,3)34-17(26)30-11-32-36(28,33-12-31-18(27)35-20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23) | RXWOJYZFCFODMQ-UHFFFAOYSA-N |
|
Citations
- 2000. Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA. Drugs in R&D. 2(5).
- 2002. Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA. Drugs in R&D. 3(3).
- An, JH, et al. 2016. Application of ionic liquid to polymorphic transformation of anti-viral/HIV drug adefovir dipivoxil. Archives of Pharmacal Research. 39(5).
- Duan, SH, et al. 2016. [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine. 36(5).
- Gu, J, et al. 2015. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pakistan Journal of Pharmaceutical Sciences. 28(4 Suppl).
- Jia, HY, et al. 2015. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. World Journal of Gastroenterology. 21(12).
- Jiang, SW, et al. 2014. Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates. World Journal of Gastroenterology. 20(45).
- Lee, YS, et al. 2016. Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B. Clinics in Orthopedic Surgery. 8(2).
- Li, X, et al. 2016. Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy. International Journal of Clinical and Experimental Medicine. 8(11).
- Lin, RZ, et al. 2015. Mechanism study on stability enhancement of adefovir dipivoxil by cocrystallization: Degradation kinetics and structure-stability correlation. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 85.
- Lin, Y, et al. 2017. Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases. Oncology Letters. 13(1).
- Luo, Q, et al. 2016. Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. Medicine. 95(50).
- Ning, H, et al. 2015. [Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology. 23(8).
- Takagi, J, et al. 2016. Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection. Internal Medicine (Tokyo, Japan). 55(12).
- Tian, L, et al. 2016. Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis. Experimental and Therapeutic Medicine. 12(4).
- Wang, G, et al. 2015. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. Drug Design, Development and Therapy. 9.
- Wang, GL, et al. 2016. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. European Review For Medical and Pharmacological Sciences. 20(5).
- Wang, Y, et al. 2015. Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy. PloS One. 10(6).
- Wang, Y, et al. 2016. Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. Experimental and Therapeutic Medicine. 11(1).
- Wei, Z, et al. 2016. Osteomalacia induced by long-term low-dose adefovir dipivoxil: Clinical characteristics and genetic predictors. Bone. 93.
- Wen, Z, et al. 2014. Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy. Hepatitis Monthly. 14(8).
- Yang, S, et al. 2016. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. Annals of Clinical Microbiology and Antimicrobials. 15.
- Zhong, JH, et al. 2016. Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. OncoTargets and Therapy. 9.
- Zhu, H, et al. 2015. [Clinical analysis of Fanconi syndrome induced by adefovir dipivoxil]. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology. 23(4).